Latest news from CTNZ
A pilot randomised controlled trial of oral doxycycline after endoscopic sinus surgery and its effects on the sinonasal microbiome.
Challis JM, Baptista MS, Ragupathy R, Lee CK, Wood AJ. Rhinology Online. 2022; 5: 49-61
AUSTRALIA & NEW ZEALAND SITE SOLUTIONS SUMMIT
2023 ARCS Annual Conference (6 – 8 June 2023)
The 2023 ARCS Annual Conference (6 – 8 June 2023) will be held at the International Convention Centre (ICC), Darling Harbour, Sydney.
9th VERVE Symposium in Sydney in December
Welcome to the NEXT LEVEL in VASCULAR EDUCATION
VEITHsymposium November 2022
49th Annual Symposium on Vascular and Endovascular Issues
Clinical Feasibility Study for Endovenous Deep Vein Valve Formation for Chronic Venous Insufficiency
Initial Results. Mr. Thodur Vasudevan, Clinical Trials NZ
SABER™ Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control...
demonstrates dose-response, safety and no impact on surgical wound healing.
SABER™ Bupivacaine Reduces Postoperative Pain Intensity and Opioid Use for 72 Hours in Soft-Tissue and Bony Surgeries
Poster presentation American Society of Anaesthesiologists, October 15 2014
Intranasal Ketorolac (ROX-888) for Postoperative Pain: A Phase 3, Double-Blind, Randomized Study
Presented at the 2008 Society for Ambulatory Anesthesia Annual Meeting
Post-Operative Pain Control with Extended-Release Bupivacaine Formulation. Clinical Trial Results in Inguinal Hernia Repair
American Hernia Society, March 15, 2008